Trial Watch: MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
Important context
- Trial eligibility (participation has strict criteria): Clinical-trial participation has study-specific eligibility criteria; registry listing does not mean a person qualifies or should enroll.
In plain English
The 30-second version
What happened?
ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
Why does it matter?
Phase 3 trials can contribute later-stage human evidence. CancerDiscoveries can track this record as results and regulatory information emerge.
What does this not prove?
A registered trial is not proof that the intervention works, is not FDA approval for this cancer or use, and is not a clinical-guideline recommendation.
Keep reading for evidence stage, limitations, study details, and sources.
What changed: ClinicalTrials.gov lists MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013) (NCT07431827) as a Phase 3 interventional cancer study. The registry status is Recruiting, with the record last updated 2026-08-17.
Study snapshot: Phase 3; Recruiting; planned enrollment 400. Conditions listed: Non-small Cell Lung Cancer. A primary outcome listed by the registry is: Disease-free Survival (DFS).
This entry tracks verified trial-registry facts. Trial registration by itself does not show that an intervention is effective, safe for a particular person, FDA-approved for this use, or recommended by clinical guidelines.
Population / Applicability
Studied in: Participants age 18 Years and older with Non-small Cell Lung Cancer who meet the study-specific registry eligibility criteria. (Adults)
Eligibility is study-specific. Registry information does not determine whether any individual should enroll in or receive the intervention.
Full evidence details
- Study design
- Not specified in this summary
- Sample size
- 400
- Primary outcome
- Disease-free Survival (DFS)
- Replication
- Unknown
Funding & Conflicts
ClinicalTrials.gov lists the lead sponsor as Merck Sharp & Dohme LLC. Sponsorship is reported for transparency and does not establish efficacy.
Regulatory status by jurisdiction
Country or region not specified
- Status
- Investigational
- Last verified
- 2026-08-17
Cancer-type scope for this record is not yet recorded.
Guideline positions
Guideline
- Position
- Not addressed
- Last verified
- 2026-08-17
Primary evidence supporting this story
- ClinicalTrials.gov — NCT07431827 (opens in a new tab) (Clinical-trial registry) NCT07431827 Primary source NCT07431827
ClinicalTrials.gov — NCT07431827. NCT07431827.
Last reviewed
Trial Watch: MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
https://cancerdiscoveries.com/discoveries/trial-watch-mk-3475a%c2%b1calderasib-mk-1084-in-completely-resected-stage-iia-iiib-n2-kras-g12cm-nsclc-mk-1084-013/
Research type: Registered later-phase trial
What This Means
ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
What This Doesn't Mean
A registered trial is not proof that the intervention works, is not FDA approval for this cancer or use, and is not a clinical-guideline recommendation.
Why It Matters
Phase 3 trials can contribute later-stage human evidence. CancerDiscoveries can track this record as results and regulatory information emerge.
Important Limitations
- Clinical-trial participation has study-specific eligibility criteria; registry listing does not mean a person qualifies or should enroll.
Primary sources
- ClinicalTrials.gov — NCT07431827 — https://clinicaltrials.gov/study/NCT07431827 (NCT07431827)
Date verified: 2026-08-17
Correction status: No correction or retraction